Emergency Approvals for COVID-19: Evolving Impact on Obligations to Patients in Clinical Care and Research.

This commentary discusses legal, ethical, and clinical issues regarding whether U S institutions and clinicians should restrict patient access to COVID-19 drugs and vaccines that have been granted emergency use authorization by the U S Food and Drug Administration [ABSTRACT FROM AUTHOR] Copyright of Annals of Internal Medicine is the property of American College of Physicians and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission However, users may print, download, or email articles for individual use This abstract may be abridged No warranty is given about the accuracy of the copy Users should refer to the original published version of the material for the full abstract (Copyright applies to all Abstracts )